259 related articles for article (PubMed ID: 22231417)
21. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
[TBL] [Abstract][Full Text] [Related]
22. A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity.
Karsai S; Adrian R; Hammes S; Thimm J; Raulin C
Arch Dermatol; 2007 Nov; 143(11):1447-9. PubMed ID: 18025375
[No Abstract] [Full Text] [Related]
23. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study.
Won CH; Kim HK; Kim BJ; Kang H; Hong JP; Lee SY; Kim CS
Int J Dermatol; 2015 Feb; 54(2):227-34. PubMed ID: 25311357
[TBL] [Abstract][Full Text] [Related]
24. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
[TBL] [Abstract][Full Text] [Related]
25. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part I: Upper facial wrinkles.
Ascher B; Talarico S; Cassuto D; Escobar S; Hexsel D; Jaén P; Monheit GD; Rzany B; Viel M
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1278-84. PubMed ID: 20337830
[TBL] [Abstract][Full Text] [Related]
26. Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines.
De Boulle K; Werschler WP; Gold MH; Bruce S; Sattler G; Ogilvie P; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
Dermatol Surg; 2018 Nov; 44(11):1437-1448. PubMed ID: 30096106
[TBL] [Abstract][Full Text] [Related]
27. New Uses of AbobotulinumtoxinA in Aesthetics.
Schlessinger J; Gilbert E; Cohen JL; Kaufman J
Aesthet Surg J; 2017 May; 37(suppl_1):S45-S58. PubMed ID: 28388720
[TBL] [Abstract][Full Text] [Related]
28. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.
Carruthers JA; Lowe NJ; Menter MA; Gibson J; Nordquist M; Mordaunt J; Walker P; Eadie N;
J Am Acad Dermatol; 2002 Jun; 46(6):840-9. PubMed ID: 12063480
[TBL] [Abstract][Full Text] [Related]
29. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides.
Carruthers A; Carruthers J; Cohen J
Dermatol Surg; 2003 May; 29(5):461-7. PubMed ID: 12752512
[TBL] [Abstract][Full Text] [Related]
30. Two different types of botulinum toxins: Is there a difference in efficacy and longevity?
Shome D; Kapoor R; Khare S
J Cosmet Dermatol; 2019 Dec; 18(6):1635-1641. PubMed ID: 31135088
[TBL] [Abstract][Full Text] [Related]
31. Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy.
Hexsel D; Brum C; Porto MD; Soirefmann M; Siega C; Schilling-Souza J; Rodrigues TC
J Drugs Dermatol; 2013 Dec; 12(12):1356-62. PubMed ID: 24301236
[TBL] [Abstract][Full Text] [Related]
32. OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.
Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Weichman BM; Garcia JK
Dermatol Surg; 2019 May; 45(5):689-699. PubMed ID: 31034447
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, double-blind, randomized, parallel-group, active-controlled, phase 3 clinical trial to compare the effectiveness and safety of two botulinum toxin type A formulations for improving moderate to severe glabellar wrinkles in Asians.
Choi SY; Koh YG; Lee YW; Son HS; Yoon YN; Kim G; Won C; Cho H; Son JS; Kim EK; Kim BJ
J Dermatolog Treat; 2024 Dec; 35(1):2359511. PubMed ID: 38880494
[TBL] [Abstract][Full Text] [Related]
34. Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin.
Beer KR; Julius H; Dunn M; Wilson F
J Cosmet Dermatol; 2014 Jun; 13(2):143-50. PubMed ID: 24910278
[TBL] [Abstract][Full Text] [Related]
35. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
Matarasso A; Shafer D
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S72-9. PubMed ID: 19945008
[TBL] [Abstract][Full Text] [Related]
36. Botulinum toxin: examining duration of effect in facial aesthetic applications.
Flynn TC
Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
[TBL] [Abstract][Full Text] [Related]
37. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Rubin M; Dover J; Maas C; Nestor M
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
[TBL] [Abstract][Full Text] [Related]
38. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
Simonetta Moreau M; Cauhepe C; Magues JP; Senard JM
Br J Dermatol; 2003 Nov; 149(5):1041-5. PubMed ID: 14632812
[TBL] [Abstract][Full Text] [Related]
39. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
40. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA.
Yu KC; Nettar KD; Bapna S; Boscardin WJ; Maas CS
Arch Facial Plast Surg; 2012; 14(3):198-204. PubMed ID: 22183059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
